36 related articles for article (PubMed ID: 17018129)
1. The impact of DAMP-mediated inflammation in severe COVID-19 and related disorders.
Parthasarathy U; Martinelli R; Vollmann EH; Best K; Therien AG
Biochem Pharmacol; 2022 Jan; 195():114847. PubMed ID: 34801526
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era.
Kasarello K; Mirowska-Guzel D
Immunotargets Ther; 2021; 10():237-246. PubMed ID: 34268256
[TBL] [Abstract][Full Text] [Related]
3. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma.
Scarisbrick JJ; Bagot M; Ortiz-Romero PL
Br J Haematol; 2021 Feb; 192(4):683-696. PubMed ID: 33095448
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis.
Simon M; Ipek R; Homola GA; Rovituso DM; Schampel A; Kleinschnitz C; Kuerten S
J Neuroinflammation; 2018 Aug; 15(1):225. PubMed ID: 30098594
[TBL] [Abstract][Full Text] [Related]
5. The immunological function of CD52 and its targeting in organ transplantation.
Zhao Y; Su H; Shen X; Du J; Zhang X; Zhao Y
Inflamm Res; 2017 Jul; 66(7):571-578. PubMed ID: 28283679
[TBL] [Abstract][Full Text] [Related]
6. Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients.
Toyoda M; Shin BH; Ge S; Mirocha J; Thomas D; Chu M; Rodriguez E; Chao C; Petrosyan A; Galera OA; Vo A; Choi J; Peng A; Kahwaji J; Jordan SC
J Immunol Res; 2017; 2017():5672523. PubMed ID: 28265581
[TBL] [Abstract][Full Text] [Related]
7. Impact of Immune-Modulatory Drugs on Regulatory T Cell.
Furukawa A; Wisel SA; Tang Q
Transplantation; 2016 Nov; 100(11):2288-2300. PubMed ID: 27490409
[TBL] [Abstract][Full Text] [Related]
8. Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS.
Thomas K; Eisele J; Rodriguez-Leal FA; Hainke U; Ziemssen T
Neurol Neuroimmunol Neuroinflamm; 2016 Jun; 3(3):e228. PubMed ID: 27213173
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes.
Lycke J
Ther Adv Neurol Disord; 2015 Nov; 8(6):274-93. PubMed ID: 26600872
[TBL] [Abstract][Full Text] [Related]
10. Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
Gelfand JM; Cotter J; Klingman J; Huang EJ; Cree BA
Neurol Neuroimmunol Neuroinflamm; 2014 Oct; 1(3):e34. PubMed ID: 25340086
[TBL] [Abstract][Full Text] [Related]
11. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
Lee F; Luevano M; Veys P; Yong K; Madrigal A; Shaw BE; Saudemont A
PLoS One; 2014; 9(7):e103254. PubMed ID: 25050704
[TBL] [Abstract][Full Text] [Related]
12. Homeostatic expansion as a barrier to lymphocyte depletion strategies.
Zwang NA; Turka LA
Curr Opin Organ Transplant; 2014 Aug; 19(4):357-62. PubMed ID: 24926701
[TBL] [Abstract][Full Text] [Related]
13. Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys.
Marco MR; Dons EM; van der Windt DJ; Bhama JK; Lu LT; Zahorchak AF; Lakkis FG; Cooper DK; Ezzelarab MB; Thomson AW
Transpl Immunol; 2013 Dec; 29(1-4):88-98. PubMed ID: 24120957
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity.
Dons EM; Raimondi G; Zhang H; Zahorchak AF; Bhama JK; Lu L; Ezzelarab M; Ijzermans JN; Cooper DK; Thomson AW
Am J Transplant; 2013 Aug; 13(8):2169-78. PubMed ID: 23635093
[TBL] [Abstract][Full Text] [Related]
15. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
Rao SP; Sancho J; Campos-Rivera J; Boutin PM; Severy PB; Weeden T; Shankara S; Roberts BL; Kaplan JM
PLoS One; 2012; 7(6):e39416. PubMed ID: 22761788
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Hu Y; Turner MJ; Shields J; Gale MS; Hutto E; Roberts BL; Siders WM; Kaplan JM
Immunology; 2009 Oct; 128(2):260-70. PubMed ID: 19740383
[TBL] [Abstract][Full Text] [Related]
17. Receptor-directed therapy of T-cell leukemias and lymphomas.
Morris JC; Waldmann TA; Janik JE
J Immunotoxicol; 2008 Apr; 5(2):235-48. PubMed ID: 18569395
[TBL] [Abstract][Full Text] [Related]
18. Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia.
Dasanu CA; Alexandrescu DT
MedGenMed; 2007 Nov; 9(4):35. PubMed ID: 18311385
[TBL] [Abstract][Full Text] [Related]
19. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood.
Lowenstein H; Shah A; Chant A; Khan A
Transpl Int; 2006 Nov; 19(11):927-36. PubMed ID: 17018129
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
